ProMIS Neurosciences Inc. (PMN) Form 8-K — Nov 12, 2026
ProMIS Neurosciences reported Q3 2026 results with a net loss of $8.2 million ($(0.89)/share) and reaffirmed that its PRECISE-AD Phase 1b trial of PMN310 in Alzheimer's disease remains on track for unblinded 12-month topline data in Q1 2027. The company highlighted encouraging blinded six-month interim data in 136 patients: zero ARIA-E events across all APOE genotypes, mild ARIA-H of 4.4%, and biomarker reductions of ~15% in plasma pTau217 and 13.3% in CSF MTBR-tau243. Cash of $44.1 million is expected to fund operations through 2027, beyond the data readout.
Key figures
- Revenue
- 0
- Cash Position
- 44100000
- Aria h rate pct
- 4.4
- Cash dec 31 2025
- 6116556
- Q3 2025 net loss
- 11580126
- Ga expense q3 2025
- 1953014
- Ga expense q3 2026
- 1905389
- Rd expense q3 2025
- 9797418
- Rd expense q3 2026
- 6710035
- Other income q3 2026
- 453556
- Apoe4 homozygotes pct
- 11
- Nine month net loss 2025
- 29045059
- Nine month net loss 2026
- 28135897
- Precise ad interim patients
- 136
- Weighted avg shares q3 2026
- 9143340
- Plasma ptau217 reduction pct
- 15
- Csf mtbr tau243 reduction pct
- 13.3
- Private placement net proceeds
- 70100000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.